Zhaoke Ophthalmology-B (06622) plummeted 31% in the afternoon. As of press release, it fell 28.43% to HK$2.14, with a turnover of HK$8.7396 million.
The Zhitong Finance App learned that Zhaoke Ophthalmology-B (06622) plummeted 31% in the afternoon. As of press release, it fell 28.43% to HK$2.14, with a turnover of HK$8.7396 million.
According to the news, Zhaoke Ophthalmology's partner Vyluma announced in June last year that the US Food and Drug Administration (FDA) has accepted a new drug application (NDA) for NVK002 (0.01% low concentration atropine) and will approve this potential treatment plan for myopia in children. The US FDA has designated the approval date for the NVK002 Prescription Drug User Payment Act (PDUFA) as January 31, 2024. According to reports, atropine is the only drug that has been proven by evidence-based medicine to effectively slow the progression of myopia, and is known as a “magic drug” in myopia prevention and control.
SPDB International previously stated that although the company's low-concentration atropine NVK-002 has excellent efficacy and a first-mover advantage, considering the gradual intensification of competition in this field, the bank lowered its peak market share forecast for this product from 25% to 22%. In addition, Zhaoke Ophthalmology's 2023 interim results show that during the reporting period, the company achieved revenue of RMB 11.3.04 million (same unit); R&D expenses of RMB 205 million, up 103.46% year on year; loss during the period was 234 million yuan, up 45.18% year on year; and loss during the adjusted period was RMB 218 million, up 57.04% year on year.